Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 20, 2016

Pfizer Launches Newly Combined CMO

Pfizer announced the launch of Pfizer CentreOne, a CMO formed by the combination of Pfizer CentreSource and Hospira One 2 One.

Pfizer’s newly combined global CMO, Pfizer CentreOne, launched on April 20, 2016. The CMO will focus specifically on API synthesis and sterile injectables fill-finish, Pfizer said in a press announcement.

Pfizer CentreOne was formed by the combination of Pfizer CentreSource and Hospira One 2 One. The formation comes after Pfizer acquired One 2 One in September 2015. The newly formed CMO plans to combine Pfizer’s knowledge of specialty APIs with One 2 One’s work with sterile injectables.

Pfizer CentreOne’s core offerings will include:

  • Small-molecule steroid and hormone intermediates and APIs

  • Custom small-molecule API synthesis

  • Sterile injectables fill-finish.

“As a combined organization, we’ve brought together the best of our manufacturing capabilities to provide a wider array of services and technologies to our biopharmaceutical partners,” said Peter Stevenson, vice-president and general manager of Pfizer CentreOne, in a press announcement. “Although Pfizer CentreOne is a new name, we’ve been providing contract manufacturing services for more than 40 years and are committed to further growing our business.”

Source: Pfizer


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.